Percentage distribution of ESC HF subtypes and no cardiac dysfunction (no dysf, n=38) among all 370 included patients, where HFvhd is HF due to valvular.

Slides:

Advertisements

Similar presentations

Heart Failure Whistle Stop Talks No 1 HFrEF and HFpEF Definitions for Diagnosis Susie Bowell BA Hons, RGN Heart Failure Specialist Nurse.

Advertisements

Current Management of Heart Failure GP clinical update 17 th June 2015 Dr Raj Bilku Consultant Cardiologist Clinical Lead Cardiology QEH.

Fig ACCF/AHA Guideline for the management of heart failure

Copyright © 2015 by the American Osteopathic Association.

Supplementary Figure 4. Kaplan-Meier curves of 12-month readmission free survival rates according to renal dysfunction with subclassification in all (A),

Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population Richard K. Cheng, MD, MS,

The Puzzle of Heart Failure With Preserved Ejection Fraction

Role of Right Ventricle and Dynamic Pulmonary Hypertension on Determining ΔVO2/ΔWork Rate FlatteningCLINICAL PERSPECTIVE by Francesco Bandera, Greta Generati,

Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.

Figure 1 Energy supply–demand matching in health and heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Figure 7 European Society of Cardiology 2016

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Prevalence of HFpEF and HFrEF by age

Nat. Rev. Cardiol. doi: /nrcardio

Johannes Steiner et al. JACC 2017;70:

Aspects to be considered by the Heart Team for the decision between TAVR and SAVR in patients at increased surgical risk. Aspects to be considered by the.

Nat. Rev. Cardiol. doi: /nrcardio

MACE rate among CAD severity groups (total 0

Challenging the Myths in Heart Failure With Reduced Ejection Fraction

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

The effect of GOODCOLL versus POORCOLL on LVEF, LVEDV and scar at 4 months. The effect of GOODCOLL versus POORCOLL on LVEF, LVEDV and scar at 4 months.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Background. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure.

Patients’ pathways to Accident and Emergency (A&E)

Bar chart of cardiac volumes and EF in the healthy individuals, HCM LVH− patients and HCM LVH+ patients. Blue bars show the indexed diastolic volumes (EDVI.

Pamela E. Scott et al. JACC 2018;71:

Comparison of CMR and echocardiography in aortic regurgitation.

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Time course of changes in left ventricular ejection fraction (LVEF) and left ventricular diastolic dimension (LVDd) in 13 patients with the development.

Cumulative survival without events during 1 year in patients with preserved systolic function (left ventricular ejection fraction (LVEF) >40%) and with.

Associations between β-blocker dosage group, predischarge heart rate group, and the primary composite outcome of death or cardiovascular rehospitalisation.

Relationship between the change in left ventricular ejection fraction (ΔLVEF) and change in left ventricular diastolic dimension (ΔLVDd) at 4 years at.

Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.

Distribution of relative percentage change ((post-AVR−pre-AVR)/pre-AVR) in the patients’ absolute pVO2 values between pre-AVR and post-AVR after 9 months.

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Patient selection. *This category included 10 patients with suspected tachyarrhythmia, 9 treated for cancer with cardiotoxic cytostatics and/or transthoracic.

UK paediatric cardiac surgery mortality rate by year for all cases and total number of procedures performed between 2000 and 2009/2010. UK paediatric cardiac.

Associations between presence of tachycardia at time of admission (heart rate ≥120/min) and the primary composite outcome of death or cardiovascular rehospitalisation,

Kaplan-Meier curve of cumulative percentage of cardiac mortality by peak flow rate category (adjusted HRs (95% CI) compared with ≥550 L/min: (

Different behaviours between group 1 and group 2 patients of the mean and SD of Δ for low frequency (LF), high frequency (HF) and total power (TP) calculated.

The amplitude of oscillation of end-tidal CO2 correlates to the amplitude of oscillation of cardiac output for both patients with heart failure (no fill)

Simpson's biplane ejection fraction (A), and two-dimensional speckle-tracking global longitudinal strain (B) in patients receiving clozapine treatment,

Supplementary Figure 4. Kaplan-Meier curves of 12-month readmission free survival rates according to renal dysfunction with subclassification in all (A),

Figure 3. Survival rates according to renal dysfunction

Representative images of coronary angiography and fractional flow reserve (FFR) from a patient who showed no resting ECG abnormality. Representative images.

Ejection fraction preoperatively and at follow-up in conventional (C) and no-touch (NT) groups. Ejection fraction preoperatively and at follow-up in conventional.

Multivariate Cox survival analysis with predictors of mortality after adjusting for comorbidities and DBT. COPD, chronic obstructive pulmonary disease;

Average left ventricular ejection fraction (LVEF) values during the 1 year of observation in patients with preserved systolic function (LVEF >40%) and.

Unadjusted means by smoking status

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

Lifetime heart failure risk*

William T. Abraham et al. JCHF 2018;j.jchf

Pro-inflammatory biomarkers in decompensated and stable HFpEF patients

Scatter plot of relationship between MWT, GLS and EF upper panel shows that GLS was closely related to MWT with worse LV function by GLS correlating to.

Increase of physical activity over time associated with lower HF risk

Algorithm for haemodynamic evaluation in the elderly.

Time to first event analysis revealed a significant difference in estimated event-free (death or hospitalisation) survival between patients with left ventricular.

Patient selection process in the present study.

Kaplan-Meier plot for the prespecified primary endpoint (CARE-HF (A) and the secondary composite endpoint (all-cause mortality and new onset heart failure.

Distribution of left atrial (LA) remodel.

Unadjusted means according to normal versus abnormal cardiac variables among current smokers. DD, diastolic dysfunction; LVM, left ventricular mass; RVFAC,

Distribution of patient baseline characteristics among included studies. Distribution of patient baseline characteristics among included studies. Each.

Constantijn Franssen et al. JCHF 2016;4:

Adjusted cumulative incidence of stroke, by sex and heart failure status. Adjusted cumulative incidence of stroke, by sex and heart failure status. The.

Relationship between 6-month all-cause mortality and the three types of heart failure adjusted for age ≥75 years, peripheral edema at admission, systolic.

Adjusted cumulative disability incidence by sex and heart failure status. Adjusted cumulative disability incidence by sex and heart failure status. The.

Presentation transcript:

Percentage distribution of ESC HF subtypes and no cardiac dysfunction (no dysf, n=38) among all 370 included patients, where HFvhd is HF due to valvular heart disease (n=61), HFrEF is HF with reduced ejection fraction (n=100), HFprEF is HF with mid range ej... Percentage distribution of ESC HF subtypes and no cardiac dysfunction (no dysf, n=38) among all 370 included patients, where HFvhd is HF due to valvular heart disease (n=61), HFrEF is HF with reduced ejection fraction (n=100), HFprEF is HF with mid range ejection fraction (n=34) and HFpEF is HF with preserved ejection fraction (n=137). EF, ejection fraction; HF, heart failure; HFmrEF, HF due to midrange EF; HFpEF, HF with preserved EF; HFrEF, HF due to reduced EF. Olav Wendelboe Nielsen et al. Open Heart 2019;6:e000928 ©2019 by British Cardiovascular Society